Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Pre-Surgery immune drug shrink early lung cancer nodules?

NCT ID NCT04047186

Disease control Sponsor: XiangNing Fu Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This pilot study tested the drug Tislelizumab given before surgery in 12 people with early-stage lung cancer who also had multiple ground-glass nodules on CT scans. The goal was to see if the drug could shrink tumors before removal. Researchers measured how many patients responded and tracked side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tislelizumab (a drug that helps the immune system fight cancer)
What this could lead to
If it works, this could point toward a way to shrink early lung tumors before surgery, possibly improving outcomes for people with multiple lung nodules.
What could go wrong
This is a very small pilot study with only 12 people, so results may not apply to everyone. The drug can cause immune-related side effects, and it is not yet proven to be better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

12 people

The number who actually took part.

Started

Jul 2019

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * not less than two GGNs on chest CT * at least one lesion is diagnosed as NSCLC from biopsy pathology * no contraindication for surgery * ECOG score of 0 or 1 * no detectable evidence of distant metastasis Exclusion Criteria: * medical history of malignancy * pregnant or breeding period * severe organ failure (heart, liver, kidney, and lung) * high risk of cerebral-cardiovascular evens * infection out of control * received or receiving chemo- and radiotherapy * history of severe reaction due to allergy or hypersensitivity * severe mental disorder * currently been enrolled in other trials * autoimmune or chronic inflammatory disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple pulmonary nodules are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung neoplasm Multiple Pulmonary Nodules non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple pulmonary nodules

Contacts and locations

Locations

  • Tongji Hospital Affiliated to Huazhong Technology Hospital

    Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.